Download Files:
Products Details
Product Description
– Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1)[1][2][3].
Web ID
– HY-44809A
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C22H29Cl2N3O4
References
– [1]Joseph H, et al. Prolyl hydroxylase inhibitors. Patent WO2011057115A1. |[2]Robert Shalwitz, et al. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha. Patent WO2011057112A1.|[3]Joseph H, et al. Compositions and methods for treating colitis. Patent WO2011057121A1.
CAS Number
– 1303513-80-5
Molecular Weight
– 470.39
SMILES
– O=C(N1CCN(CC(C=CN2CC3=CC=C(Cl)C=C3)=C(O)C2=O)CC1)OC(C)(C)C.[H]Cl
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– HIF/HIF Prolyl-Hydroxylase
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
